Edition: Global  
One News Page
“Probably the fastest-access news portal in the world”
"Martin Shkreli" News  |<  Page 1  >> 
2
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 

The New York Post: Martin Shkreli’s early days on Wall Street chronicled in convicted inside trader’s book


MarketWatch

Over / Under: Watch Migos Rate Martin Shkreli, Monogamy, and Soup

from our series Over / Under. Watch now!
Pitchfork

Videos for "Martin Shkreli"

News video: Evzio Price Hike

Evzio Price Hike 01:07

No description.
Source: Wochit News -

 

Raekwon - The Wild

raekwon - the wild
Hip-hop icon matches renewed ambition to the benefit of experience... 25 years after the tightly-knit nine-man cell broke out of their Staten Island confines to become the all-conquering juggernaut..
Clash

The Martin Shkreli of defense contracting?


SeekingAlpha Also reported by •Huffington Post

United States: THE LATEST: Losing Bidder For Pharmaceutical Triggers FTC Investigation, Fix, And $100 Million Fine In Non-HSR-Reportable Transaction - McDermott Will & Emery

A private lawsuit filed by Retrophin Inc. (Retrophin), under then-CEO Martin Shkreli, likely triggered an investigation by the FTC into a consummated transaction.
Mondaq

Thursday's Morning Email: The Aftermath Of The London Terror Attack

-TOP STORIES- (And want to get The Morning Email each weekday? Sign up here.) *INSIDE THE LONDON TERROR ATTACK *London police have arrested several people in overnight raids in connection with the..
Huffington Post

Something weird's going on with the doctors prescribing one of pharma’s most controversial blockbuster drugs (MNK)

something weird's going on with the doctors prescribing one of pharma’s most controversial blockbuster drugs (mnk)
· *The effectiveness of Mallinckrodt Pharmaceuticals' blockbuster drug H.P. Acthar over cheaper alternatives is being questioned by an Oregon State University study.* · *The drug is prescribed by a..
Business Insider

Martin Shkreli keeps buying up the personal domain names of journalists who write about him

martin shkreli keeps buying up the personal domain names of journalists who write about him
Former pharmaceutical executive Martin Shkreli is trolling journalists who have written about him by purchasing the internet domains associated with their names. A recent look at the domains..
Business Insider

Martin Shkreli’s former biotech company Retrophin is moving to West Coast

Retrophin, a San Diego-based biotech that Martin Shkreli co-founded and led before his ouster in 2014, plans to close its research and development office in Cambridge, Massachusetts by the end of the..
bizjournals

WeKiki is the perfect alternative for anyone missing blab.im

Remember blab.im? During its short lifetime, the popular video discussion site developed an enthusiastic following of users, including notorious pharma-bro Martin Shkreli. According to CEO Shaan Puri,..
The Next Web

It's another day of 'good news is bad news' at Bill Ackman's nightmare stock (VRX)

it's another day of 'good news is bad news' at bill ackman's nightmare stock (vrx)
Here's the good news: Valeant Pharmaceuticals has raised $1.1 billion dollars in asset sales it will use to pay down debt. It's also taking this opportunity to refinance more of its $30 billion..
Business Insider

Shkreli dubbed a “serial fraudster” by his ex-lawyer in court

shkreli dubbed a “serial fraudster” by his ex-lawyer in court
(credit: Drew Angerer/Getty Images) In court documents, Evan Greebel, Martin Shkreli’s former lawyer, alleges that the...
WorldNews

Martin Shkreli, 'most hated man in America,' takes calls from Cal students in bizarre Facebook Live

For a few hours Monday, Martin Shkreli, a pharmaceutical executive most famous for raising the price of the drug Daraprim by 5,000 percent, was made an administrator on a popular UC Berkeley Facebook..
SFGate

Pharma CEO insists $89,000 drug will be affordable for patients

CHICAGO — When Marathon Pharmaceuticals’ $89,000 price for a year’s supply of its newly approved muscular dystrophy drug sparked outrage this month, the company’s CEO responded with another..
SFGate

What you need to know on Wall Street right now

what you need to know on wall street right now
*Welcome to Finance Insider, Business Insider's summary of the top stories of the past 24 hours.* Kraft Heinz, the consumer giant backed by Brazilian billionaire Jorge Lehmann and Warren Buffett,..
Business Insider

Thanks, Martin Shkreli, for the Dumbest Advice Ever on Drug Pricing

The former CEO who jacked up the price of a rare-disease drug by nearly 5,500% in 2015 has advice for President Trump on drug pricing.
Motley Fool

​Shkreli defends drug prices, spars with protesters at heated UMass Boston event

Controversial pharmaceutical executive Martin Shkreli used a speaking appearance at UMass Boston on Thursday to defend the high cost of some rare disease treatments, including a drug developed by..
bizjournals

We dug into the drug company Martin Shkreli sold out to the Feds, and man is it ugly

we dug into the drug company martin shkreli sold out to the feds, and man is it ugly
· *Medicare spent over $500 million on a drug called Acthar in 2015.* · *The drug, which has never been tested by the FDA, is the only one in the top-20 for Medicare that isn't considered..
Business Insider

Despite Protests And A Fire Alarm, Martin Shkreli's Show Goes On At Harvard

The former pharmaceutical executive — who earned notoriety for jacking up the price of a life-saving drug — spoke to a student group Wednesday night, though about a tenth of his audience walked..
NPR


You Might Like


 |<  Page 1  >> 
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+